{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:47:22Z","timestamp":1790498842295,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Associazione Italiana per la Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC)","award":["IG 14214"],"award-info":[{"award-number":["IG 14214"]}]},{"name":"Associazione Italiana per la Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC)","award":["IG 2016"],"award-info":[{"award-number":["IG 2016"]}]},{"name":"Associazione Italiana per la Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC)","award":["Id 19026 to AA"],"award-info":[{"award-number":["Id 19026 to AA"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.lungcan.2018.11.038","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:41:46Z","timestamp":1543498906000},"page":"153-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC"],"prefix":"10.1016","volume":"127","author":[{"given":"Giulia","family":"Mazzaschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Missale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Canetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Veneziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Goldoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-7399","authenticated-orcid":false,"given":"Paola","family":"Bordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Quaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.11.038_bib0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"6382","key":"10.1016\/j.lungcan.2018.11.038_bib0010","first-page":"1350","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Sci. Mar."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.lungcan.2018.11.038_bib0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/imt-2016-0150","article-title":"PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data","volume":"9","author":"Aguiar","year":"2017","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.lungcan.2018.11.038_bib0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2018.11.038_bib0030","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-16-3146","article-title":"PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors","volume":"23","author":"Kluger","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.lungcan.2018.11.038_bib0035","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2018.11.038_bib0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2018.11.038_bib0045","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju435","article-title":"Objective measurement and clinical significance of TILs in non-small cell lung cancer","volume":"107","author":"Schalper","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.lungcan.2018.11.038_bib0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jtho.2016.01.015","article-title":"The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer","volume":"11","author":"Bremnes","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2018.11.038_bib0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2018.11.038_bib0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4049\/jimmunol.1701269","article-title":"Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity","volume":"200","author":"Engelhard","year":"2018","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.038_bib0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2018.01.022","article-title":"Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer","volume":"117","author":"Barua","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.11.038_bib0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10238-010-0120-7","article-title":"Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors","volume":"11","author":"Mariucci","year":"2011","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"6332","key":"10.1016\/j.lungcan.2018.11.038_bib0085","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"issue":"7620","key":"10.1016\/j.lungcan.2018.11.038_bib0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.lungcan.2018.11.038_bib0095","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.038_bib0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","article-title":"Predictors of responses to immune checkpoint blockade in advanced melanoma","volume":"8","author":"Jacquelot","year":"2017","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.lungcan.2018.11.038_bib0115","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.038_bib0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","article-title":"Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab","volume":"13","author":"Tanizaki","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2018.11.038_bib0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2018.11.038_bib0130","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2217\/imt-2017-0175","article-title":"Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab","volume":"10","author":"Facchinetti","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lungcan.2018.11.038_bib0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2018.11.038_bib0140","doi-asserted-by":"crossref","first-page":"1154249","DOI":"10.1080\/2162402X.2016.1154249","article-title":"Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments","volume":"5","author":"Cariani","year":"2016","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.lungcan.2018.11.038_bib0145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1078-0432.CCR-17-2156","article-title":"Low PD-1 expression in cytotoxic CD8+ tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value","volume":"24","author":"Mazzaschi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0150","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lungcan.2018.11.038_bib0155","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.lungcan.2018.11.038_bib0160","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2018.11.038_bib0165","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ni1114","article-title":"Interplay of natural killer cells and their receptors with the adaptive immune response","volume":"5","author":"Raulet","year":"2004","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.lungcan.2018.11.038_bib0170","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/PPO.0000000000000156","article-title":"Natural killer cell adoptive transfer therapy: exploiting the first line of defense against Cancer","volume":"21","author":"Davis","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0175","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3389\/fimmu.2017.01194","article-title":"Natural Killer cell response to chemotherapy-stressed cancer cells: role in immune surveillance","volume":"8","author":"Zingoni","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2018.11.038_bib0180","first-page":"e1412901","article-title":"Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide","volume":"7","author":"Pellegatta","year":"2018","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.lungcan.2018.11.038_bib0185","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1158\/1078-0432.CCR-10-2084","article-title":"Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy","volume":"17","author":"Fregni","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2018.11.038_bib0190","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00262-016-1901-y","article-title":"Blockade of programmed death-1\/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells","volume":"65","author":"Kamata","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"March (1)","key":"10.1016\/j.lungcan.2018.11.038_bib0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-018-0328-8","article-title":"Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients","volume":"6","author":"Subrahmanyam","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2018.11.038_bib0200","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2018.11.038_bib0205","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.4049\/jimmunol.1001783","article-title":"Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults","volume":"186","author":"Duraiswamy","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/imr.12411","article-title":"T follicular regulatory cells","volume":"271","author":"Sage","year":"2016","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2018.11.038_bib0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/intimm\/dxx073","article-title":"Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma","volume":"30","author":"Takeuchi","year":"2018","journal-title":"Int. Immunol."},{"issue":"7652","key":"10.1016\/j.lungcan.2018.11.038_bib0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"4","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2018.11.038_bib0225","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.lungcan.2018.11.038_bib0230","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2018.11.038_bib0235","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0240","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"15","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2018.11.038_bib0245","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.4049\/jimmunol.176.3.1582","article-title":"CD4+CD25+ t regulatory cells suppress NK cell-mediated immunotherapy of Cancer","volume":"176","author":"Smyth","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0250","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-065X.2006.00445.x","article-title":"The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression","volume":"214","author":"Ghiringhelli","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0255","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/cmi.2013.2","article-title":"Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy","volume":"10","author":"Pedroza-Pacheco","year":"2013","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.lungcan.2018.11.038_bib0260","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nri3605","article-title":"Homeostatic control of regulatory T cell diversity","volume":"14","author":"Liston","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.lungcan.2018.11.038_bib0265","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-Cell lung Cancer Profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"September","key":"10.1016\/j.lungcan.2018.11.038_bib0270","article-title":"Tumor mutation burden: is it ready for the clinic?","author":"Goto","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218306780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218306780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T04:43:36Z","timestamp":1573015416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218306780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":54,"alternative-id":["S0169500218306780"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.11.038","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.11.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}